Evidence map›Paper›PMID 34956141›Full record

ArticleFrontiers in microbiology2021

Alexandr Shevtsov, Larissa Lukhnova, Uinkul Izbanova, Jean-Philippe Vernadet, Marat Kuibagarov, Asylulan Amirgazin, Yerlan Ramankulov, Gilles Vergnaud

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Pathogens (Basel, Switzerland) · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. New Research on thePathogens (Basel, Switzerland) · 2023
    Article
  7. Article
  8. Molecular Typing of UkrainianMicroorganisms · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Alexandr ShevtsovNational Center for Biotechnology, Nur Sultan, Kazakhstan.
Larissa LukhnovaNational Scientific Center for Especially Dangerous Infections Named by Masgut Aykimbayev, Almaty, Kazakhstan.
Uinkul IzbanovaNational Scientific Center for Especially Dangerous Infections Named by Masgut Aykimbayev, Almaty, Kazakhstan.
Jean-Philippe VernadetCEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Université Paris-Saclay, Gif-sur-Yvette, France.
Marat KuibagarovNational Center for Biotechnology, Nur Sultan, Kazakhstan.
Asylulan AmirgazinNational Center for Biotechnology, Nur Sultan, Kazakhstan.
Yerlan RamankulovNational Center for Biotechnology, Nur Sultan, Kazakhstan.
Gilles VergnaudCEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Université Paris-Saclay, Gif-sur-Yvette, France.
National Center for Biotechnology · KZCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article describes

Indexed as

Bacillus anthracisevolutionMLVA (multiple locus variable number tandem repeats analysis)NeolithicPaleolithicphylogeographysingle nucleotide polymorphism (SNP)whole genome sequencing (WGS)

Identifiers

PMID34956141
PMCPMC8692834
OpenAlexW4200473923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.